@article{5768dee2cf8a4b26adebfd5ca32db12c,
title = "NCCN Guidelines{\textregistered} insights acute lymphoblastic Leukemia, Version 1.2017 featured updates to the NCCN guidelines",
abstract = "The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.",
author = "Brown, {Patrick A.} and Bijal Shah and Amir Fathi and Matthew Wieduwilt and Anjali Advani and Patricia Aoun and Barta, {Stefan K.} and Boyer, {Michael W.} and Teresa Bryan and Burke, {Patrick W.} and Ryan Cassaday and Coccia, {Peter F.} and Coutre, {Steven E.} and Damon, {Lloyd E.} and DeAngelo, {Daniel J.} and Olga Frankfurt and Greer, {John P.} and Kantarjian, {Hagop M.} and Klisovic, {Rebecca B.} and Gary Kupfer and Mark Litzow and Arthur Liu and Ryan Mattison and Jae Park and Jeffrey Rubnitz and Ayman Saad and Uy, {Geoffrey L.} and Wang, {Eunice S.} and Gregory, {Kristina M.} and Ndiya Ogba",
note = "Publisher Copyright: {\textcopyright} 2017 JNCCN-Journal of the National Comprehensive Cancer Network.",
year = "2017",
month = sep,
day = "1",
doi = "10.6004/jnccn.2017.0147",
language = "English",
volume = "15",
pages = "1091--1102",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
number = "9",
}